Zhuhai Tengbai Pharmaceutical Co., Ltd.

main purpose: To evaluate the antitumor effect of TB01 in patients with advanced colorectal cancer. Secondary purpose: 1) To evaluate the pharmacokinetic (PK) characteristics of TB01 in patients with advanced colorectal cancer 2) To evaluate the safety and tolerability of TB01 in patients with advanced colorectal cancer. Exploratory Purpose: 1) To explore the correlation between the expression of integrins in tumor tissue and disease prognosis; 2) To explore the changes of cytokines and their receptors (VEGF, VEGFR) in vivo before and after treatment and their correlation with disease prognosis; 3) To explore the immunogenicity of TB01 in patients with advanced colon cancer and the effect of anti-drug antibody (ADA) production on PK, efficacy and safety.

main purpose To evaluate the tolerability and safety of single-dose and multiple-dose of HYD-PEP06 for injection in patients with advanced solid tumors, and to determine its maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). secondary purpose (1) To evaluate the pharmacokinetics of HYD-PEP06 for injection in patients with advanced solid tumors; (2) Preliminary evaluation of the efficacy of HYD-PEP06 for injection in the treatment of patients with advanced solid tumors; exploratory purpose (1) Preliminary exploration of the immunogenic response of HYD-PEP06 for injection in humans and the effect of anti-drug antibody production on PK/PD, efficacy and safety; (2) Preliminarily explore the effect of HYD-PEP06 for injection on cytokines EGF/VEGF.